|
Jim Lisbakken focuses on business transactions, licensing, and joint ventures and corporations specifically in the life sciences and technology industries. He has experience serving as outside general counsel to boards of directors of public and private companies, and has advised clients on numerous strategic alliances and technology agreements with Eli Lilly, GlaxoSmithKline, Serono, Johnson & Johnson, Abbott Laboratories and other international life sciences companies. Jim also has experience with financing transactions, acquisitions and spin-outs.
Professional Recognition
- Named Best Lawyers’ Seattle, "Lawyer of the Year" for Technology Law, 2017
- Named Best Lawyers’ Seattle, "Lawyer of the Year" for Biotechnology Law, 2016
- Named Best Lawyers’ Seattle, "Technology Law Lawyer of the Year," 2015
- Named Best Lawyers’ Seattle, "Biotechnology Law Lawyer of the Year," 2012
- Listed in Super Lawyers Magazine, "Washington's Super Lawyers," 2005 – 2018
- Listed in Best Lawyers in America: Biotechnology and Life Sciences Practice; Corporate Law; Mergers and Acquisitions Law; Technology Law, 2007 – 2024
Professional Leadership
- American Bar Association, Business and Intellectual Property Sections
- Washington State Bar Association, Business and Intellectual Property Sections
- Licensing Executives Society, Former Member
- Northwest Biotechnology Series, Organizing Committee
- Washington Biotechnology and Biomedical Association, founding Board of Directors, Former Member
Related Employment
- Genetic Systems Corporation, Seattle, WA, Executive Vice President, General Counsel and Director, 1983 – 1985
- Westinghouse Nuclear Power Divisions, 1967 – 1970
